Panbela Therapeutics (OTCMKTS:PBLA – Get Free Report) is expected to issue its resultson Friday, November 13th. Analysts expect the company to post earnings of ($2,640.00) per share for the quarter.
Panbela Therapeutics Price Performance
Shares of Panbela Therapeutics stock opened at $0.01 on Friday. Panbela Therapeutics has a 12-month low of $0.00 and a 12-month high of $0.10. The company’s 50-day moving average price is $0.01 and its 200-day moving average price is $0.01.
About Panbela Therapeutics
Panbela Therapeutics, Inc is a biotechnology company focused on developing novel therapies for cancer and other serious diseases. The company’s research has centered on treatments that target polyamine metabolism, a biological process associated with tumor growth and cancer progression.
Panbela’s lead investigational product has been ivospemin, formerly known as SBP-101, which has been studied in combination with standard treatments for pancreatic ductal adenocarcinoma and other solid tumors.
See Also
- Five stocks we like better than Panbela Therapeutics
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
